BioMarin Pharmaceuticals
BMRN
BMRN
537 hedge funds and large institutions have $12B invested in BioMarin Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 199 increasing their positions, 182 reducing their positions, and 92 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
537
Holders Change
-11
Holders Change %
-2.01%
% of All Funds
7.15%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.09%
New
90
Increased
199
Reduced
182
Closed
92
Calls
$141M
Puts
$128M
Net Calls
+$12.2M
Net Calls Change
-$27.7M
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$164M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$65.8M |
| 3 |
BlackRock
New York
|
+$58.5M |
| 4 |
Dodge & Cox
San Francisco,
California
|
+$55.7M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$49.8M |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
-$83.2M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$81.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$53.7M |
| 4 |
Neuberger Berman Group
New York
|
-$52.8M |
| 5 |
Primecap Management
Pasadena,
California
|
-$44.6M |